Kronos BioÂ Inc (KRON)

Name: Kronos BioÂ Inc (KRON) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Kronos BioÂ Inc (KRON)

Stock Card

$0.88

$0.00 (0.00%)

As on 16-Jul-2025 09:30EDT

Market cap

$54 Mln

Revenue (TTM)

$9 Mln

P/E Ratio

P/B Ratio

0.7

Div. Yield

0 %

Kronos BioÂ Inc (KRON) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 0.88 High: 0.88

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.6 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

0.8
Debt to Equity

0
Book Value

$--
EPS

$-1.1
Face value

--
Shares outstanding

60,969,200

6 Years Aggregate

CFO

$-346.87 Mln

EBITDA

$-507.51 Mln

Net Profit

$-477.29 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Kronos BioÂ Inc (KRON)	-7.4	-1.4	1.4	-38.9	-43.7	--	--
BSE Sensex^*	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 16-Jul-2025 | *As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2024	2023	2022	2021
Kronos BioÂ Inc (KRON)	-23.8	-22.8	-88.1	-54.5
S&P Small-Cap 600	7.0	13.9	-17.4	25.3
BSE Sensex	8.1	18.7	4.4	22.0

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Kronos BioÂ Inc (KRON)	0.9	53.7	9.2	-64.5	-550.5	-67.5	--	0.7
Blueprint Medicines Corp (BPMC)	129.5	8,371.7	562.1	-155.7	-19.3	-47.5	--	24.4
OncoCyte Corp (OCX)	2.8	91.5	3.8	-58.2	-1,349.4	-584.1	--	7.9

Shareholding Pattern

View Details

About Kronos BioÂ Inc (KRON)

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor... development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in preclinical development for the treatment of Sjogren's disease. The company was incorporated in 2017 and is headquartered in San Mateo, California. As of June 20, 2025, Kronos Bio, Inc. operates as a subsidiary of Concentra Biosciences, LLC. Read more

President, CEO & Director

Dr. Norbert W. Bischofberger Ph.D.
President, CEO & Director

Dr. Norbert W. Bischofberger Ph.D.
Headquarters

San Mateo, CA
Website

https://www.kronosbio.com

FAQs for Kronos BioÂ Inc (KRON)

What is the current share price of Kronos BioÂ Inc (KRON) Today?

The share price of Kronos BioÂ Inc (KRON) is $0.88 (NASDAQ) as of 16-Jul-2025 09:30 EDT. Kronos BioÂ Inc (KRON) has given a return of -43.73% in the last 3 years.

What is the current PB & PE ratio of Kronos BioÂ Inc (KRON)?

Since, TTM earnings of Kronos BioÂ Inc (KRON) is negative, P/E ratio is not available.
The P/B ratio of Kronos BioÂ Inc (KRON) is 0.67 times as on 16-Jul-2025, a 87 discount to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2024	-0.67	0.65
2023	-0.65	0.46
2022	-0.71	0.37
2021	-5.05	2.18
2020	-22.01	3.03

What is the 52 Week High and Low of Kronos BioÂ Inc (KRON)?

The 52-week high and low of Kronos BioÂ Inc (KRON) are Rs -- and Rs -- as of 31-Aug-2026.

What is the market cap of Kronos BioÂ Inc (KRON)?

Kronos BioÂ Inc (KRON) has a market capitalisation of $ 54 Mln as on 16-Jul-2025. As per SEBI classification, it is a Small Cap company.

Should I invest in Kronos BioÂ Inc (KRON)?

Before investing in Kronos BioÂ Inc (KRON), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.